Drug Profile
Pentoxifylline vaginal - Prokrea
Alternative Names: Pentoxifylline vaginal; PKB-171Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator PROCREA BioSciences
- Class Anti-inflammatories; Anticoagulants; Antithrombotics; Infertility therapies; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
- Mechanism of Action Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Male infertility
Most Recent Events
- 22 Oct 2020 Phase-II development is ongoing for Male infertility in Spain (Vaginal) (PROCREA BioSciences pipeline, October 2020)
- 25 Jul 2019 Prokrea terminates a phase II trial in Male infertility in Spain (Vaginal) (EudraCT2016-003993-42)
- 17 Apr 2017 Chemical structure information added